title: New office and new leader aim to streamline FDA cancer drug review process.
authors.forename: Renee
authors.initials: R
authors.lastname: Twombly
mesh_terms: D000970:Antineoplastic Agents; D002986:Clinical Trials as Topic; D017277:Drug Approval / Q000379:methods / Q000458:organization & administration*; D015507:Drugs, Investigational / Q000592:standards; D019317:Evidence-Based Medicine; D006076:Government; D006801:Humans; D008495:Medical Oncology / Q000592:standards*; D009316:National Institutes of Health (U.S.); D009936:Organizational Innovation; D009937:Organizational Objectives; D012955:Societies, Medical; D014481:United States; D014486:United States Food and Drug Administration / Q000458:organization & administration*
chemical_list: D000970:Antineoplastic Agents; D015507:Drugs, Investigational